Cargando…
Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
PURPOSE: Several predictive models have been developed to predict the pathological complete response (pCR) after neoadjuvant chemotherapy (NAC); however, few are broadly applicable owing to radiologic complexity and institution-specific clinical variables, and none have been externally validated. Th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475713/ https://www.ncbi.nlm.nih.gov/pubmed/37272242 http://dx.doi.org/10.4048/jbc.2023.26.e14 |
_version_ | 1785100774029656064 |
---|---|
author | Jung, Ji-Jung Kim, Eun-Kyu Kang, Eunyoung Kim, Jee Hyun Kim, Se Hyun Suh, Koung Jin Kim, Sun Mi Jang, Mijung Yun, Bo La Park, So Yeon Lim, Changjin Han, Wonshik Shin, Hee-Chul |
author_facet | Jung, Ji-Jung Kim, Eun-Kyu Kang, Eunyoung Kim, Jee Hyun Kim, Se Hyun Suh, Koung Jin Kim, Sun Mi Jang, Mijung Yun, Bo La Park, So Yeon Lim, Changjin Han, Wonshik Shin, Hee-Chul |
author_sort | Jung, Ji-Jung |
collection | PubMed |
description | PURPOSE: Several predictive models have been developed to predict the pathological complete response (pCR) after neoadjuvant chemotherapy (NAC); however, few are broadly applicable owing to radiologic complexity and institution-specific clinical variables, and none have been externally validated. This study aimed to develop and externally validate a machine learning model that predicts pCR after NAC in patients with breast cancer using routinely collected clinical and demographic variables. METHODS: The electronic medical records of patients with advanced breast cancer who underwent NAC before surgical resection between January 2017 and December 2020 were reviewed. Patient data from Seoul National University Bundang Hospital were divided into training and internal validation cohorts. Five machine learning techniques, including gradient boosting machine (GBM), support vector machine, random forest, decision tree, and neural network, were used to build predictive models, and the area under the receiver operating characteristic curve (AUC) was compared to select the best model. Finally, the model was validated using an independent cohort from Seoul National University Hospital. RESULTS: A total of 1,003 patients were included in the study: 287, 71, and 645 in the training, internal validation, and external validation cohorts, respectively. Overall, 36.3% of the patients achieved pCR. Among the five machine learning models, the GBM showed the highest AUC for pCR prediction (AUC, 0.903; 95% confidence interval [CI], 0.833–0.972). External validation confirmed an AUC of 0.833 (95% CI, 0.800–0.865). CONCLUSION: Commonly available clinical and demographic variables were used to develop a machine learning model for predicting pCR following NAC. External validation of the model demonstrated good discrimination power, indicating that routinely collected variables were sufficient to build a good prediction model. |
format | Online Article Text |
id | pubmed-10475713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Breast Cancer Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-104757132023-09-05 Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Jung, Ji-Jung Kim, Eun-Kyu Kang, Eunyoung Kim, Jee Hyun Kim, Se Hyun Suh, Koung Jin Kim, Sun Mi Jang, Mijung Yun, Bo La Park, So Yeon Lim, Changjin Han, Wonshik Shin, Hee-Chul J Breast Cancer Original Article PURPOSE: Several predictive models have been developed to predict the pathological complete response (pCR) after neoadjuvant chemotherapy (NAC); however, few are broadly applicable owing to radiologic complexity and institution-specific clinical variables, and none have been externally validated. This study aimed to develop and externally validate a machine learning model that predicts pCR after NAC in patients with breast cancer using routinely collected clinical and demographic variables. METHODS: The electronic medical records of patients with advanced breast cancer who underwent NAC before surgical resection between January 2017 and December 2020 were reviewed. Patient data from Seoul National University Bundang Hospital were divided into training and internal validation cohorts. Five machine learning techniques, including gradient boosting machine (GBM), support vector machine, random forest, decision tree, and neural network, were used to build predictive models, and the area under the receiver operating characteristic curve (AUC) was compared to select the best model. Finally, the model was validated using an independent cohort from Seoul National University Hospital. RESULTS: A total of 1,003 patients were included in the study: 287, 71, and 645 in the training, internal validation, and external validation cohorts, respectively. Overall, 36.3% of the patients achieved pCR. Among the five machine learning models, the GBM showed the highest AUC for pCR prediction (AUC, 0.903; 95% confidence interval [CI], 0.833–0.972). External validation confirmed an AUC of 0.833 (95% CI, 0.800–0.865). CONCLUSION: Commonly available clinical and demographic variables were used to develop a machine learning model for predicting pCR following NAC. External validation of the model demonstrated good discrimination power, indicating that routinely collected variables were sufficient to build a good prediction model. Korean Breast Cancer Society 2023-03-28 /pmc/articles/PMC10475713/ /pubmed/37272242 http://dx.doi.org/10.4048/jbc.2023.26.e14 Text en © 2023 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jung, Ji-Jung Kim, Eun-Kyu Kang, Eunyoung Kim, Jee Hyun Kim, Se Hyun Suh, Koung Jin Kim, Sun Mi Jang, Mijung Yun, Bo La Park, So Yeon Lim, Changjin Han, Wonshik Shin, Hee-Chul Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer |
title | Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer |
title_full | Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer |
title_fullStr | Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer |
title_full_unstemmed | Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer |
title_short | Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer |
title_sort | development and external validation of a machine learning model to predict pathological complete response after neoadjuvant chemotherapy in breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475713/ https://www.ncbi.nlm.nih.gov/pubmed/37272242 http://dx.doi.org/10.4048/jbc.2023.26.e14 |
work_keys_str_mv | AT jungjijung developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT kimeunkyu developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT kangeunyoung developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT kimjeehyun developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT kimsehyun developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT suhkoungjin developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT kimsunmi developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT jangmijung developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT yunbola developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT parksoyeon developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT limchangjin developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT hanwonshik developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer AT shinheechul developmentandexternalvalidationofamachinelearningmodeltopredictpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer |